Grazoprevir
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic hepatitis C virus infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antivirals for treatment of hcv infections
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP11
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Grazoprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more64.1% AI-predicted activityagainst MRSA50+ registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more63.6% AI-predicted activityagainst MRSA50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome63.6% AI-predicted activityagainst MRSA6 registered studies
- Nafarelin AcetateExisting use: Endometriosis63.6% AI-predicted activityagainst MRSA12 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents63.6% AI-predicted activityagainst MRSA1 registered study
- Vinorelbine TartrateExisting use: Cancer, Neoplasm63.6% AI-predicted activityagainst MRSA50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis63.5% AI-predicted activityagainst MRSANo documented evidence found
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances63.4% AI-predicted activityagainst MRSA50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema63.4% AI-predicted activityagainst MRSA33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria63.3% AI-predicted activityagainst MRSA39 registered studies
- LypressinExisting use: Vasopressin and analogues63.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
NCT01717326 · start 2013-02-07
Registered record
- Registry ID
- NCT01717326
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir; Elbasvir; Placebo to Elbasvir; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-02-07
- Completion
- 2015-05-06
- Enrolment
- 573
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionGrazoprevir; Elbasvir; Placebo to Elbasvir; RibavirinPhasePhase 2Registry statusCompletedA Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)
NCT01716156 · start 2013-01-18
Registered record
- Registry ID
- NCT01716156
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-01-18
- Completion
- 2014-03-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionGrazoprevir; RibavirinPhasePhase 2Registry statusCompletedA Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
NCT01710501 · start 2012-12-07
Registered record
- Registry ID
- NCT01710501
- Conditions
- Chronic Hepatitis C (CHC)
- Interventions
- Grazoprevir; pegylated interferon alfa-2b; Ribavirin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-12-07
- Completion
- 2014-01-29
- Enrolment
- 87
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis C (CHC)InterventionGrazoprevir; pegylated interferon alfa-2b; Ribavirin; PlaceboPhasePhase 2Registry statusCompletedEvaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)
NCT01547312 · start 2012-05
Registered record
- Registry ID
- NCT01547312
- Conditions
- Chronic Hepatitis C
- Interventions
- Peg-Interferon; Liver Samples from FNA; Liver Samples from CNB; Blood Samples; Ribavirin; 800 mg Grazoprevir; 100 mg Grazoprevir; Liver samples from CNB and FNA
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2012-05
- Completion
- 2012-11
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis CInterventionPeg-Interferon; Liver Samples from FNA; Liver Samples from CNB; Blood Samples +4 morePhasePhase 1Registry statusWithdrawnA Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
NCT00998985 · start 2010-02-23
Registered record
- Registry ID
- NCT00998985
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-02-23
- Completion
- 2012-11-08
- Enrolment
- 91
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionGrazoprevir; PlaceboPhasePhase 1Registry statusCompleted